Glenmark Pharmaceuticals plans to launch over 10 products in FY16

26 Aug 2015 Evaluate

Glenmark Pharmaceuticals (GPL) is planning to launch 10-12 new products in the domestic market during the current financial year (2015-16) and hopes to report a growth of 18-20 percent. The company wants to increase its focus on the Indian market across four key areas, including dermatology, diabetes, cardiology and respiratory segments. The company derives about 26% of its revenues from the India, which is its second largest market.

GPL is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).

Glenmark Pharma Share Price

1992.70 -8.35 (-0.42%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×